Jump to content


Congrats to Margaret, Platinum Member with 1,000 posts and 10 Years of Forums Membership!


Photo

Antitransforming growth factor (Anti-TGF) -[beta] therapy in fibrosis: recent progress and implications for systemic sclerosis


  • Please log in to reply
No replies to this topic

#1 janey

janey

    Platinum Member

  • ISN Support Specialists
  • PipPipPipPipPipPipPipPipPipPip
  • 2,118 posts
  • Location:New Mexico

Posted 04 November 2008 - 04:28 AM

Antitransforming growth factor (Anti-TGF) -[beta] therapy in fibrosis: recent progress and implications for systemic sclerosis.

Anti-TGF-[beta] therapies promise to have a major impact in systemic sclerosis. Significant concerns regarding efficacy and safety need to be addresed. The identification of optimal candidates for therapy, and of biomarkers of safety and efficacy, are critical challenges ahead. J.Varga. Current Opinion in Rheumatology. 20(6):720-728, November 2008. (Also see: Causes of Scleroderma: Proteins)

This item was posted in the ISN Newsroom. Check the Newsroom every day for the latest scleroderma medical and support information.
Janey Willis
ISN Support Specialist
(Retired) ISN Assistant Webmaster
(Retired) ISN News Director
(Retired) ISN Technical Writer for Training Manuals
International Scleroderma Network (ISN)